[ad_1]
New afterthought analysisthis is Data from SELECTION phosphorusRabbit 3 program Published on Crohn’s Disease and Colitis in Europe organization (ECCO) Virtual Meeting
Mechelen, Belgium; 10 July 2021, 11.10 CET; Galapagos NV ((Euronext and Nasdaq:GLPG) Today announced the new afterwards analysis From The third phase Choose a program, stand by Activity and tolerance Figotinib, A kind Once a day, Oral JAK1 priority inhibitor, Under investigation It is used to treat patients with moderate to severe active ulcerative colitis (UC).These data are in European Crohn’s disease and colitis organization (ECCO) 16th Annual Meeting.
A kind afterwards Analysis of the induction study data from SELECTION showed that the patient-reported stool frequency (SF) and rectal bleeding (RB) patient-reported outcome (PRO) significantly improved, as early as receiving 200 mg of fegotinib These results were observed in patients with moderately to severely active UC patients daily compared with placebo. These findings have been observed in both patients who have not received biologic therapy and those who have received biologic therapy. In induction study A, more patients who received filgotinib 200mg and placebo reached a composite score of RB=0 and SF≤1 as early as day 9 (biological trial; filgotinib 200mg 18.8%, placebo 9.5%, p< 0.05) and as early as day 7 in induction study B (biological experience; filgotinib 200mg 10.7%; placebo 4.2%, p<0.05).1
further afterwards The analysis of the SELECTION maintenance study reported the proportion of patients who did not use steroids at various time points before remission was reached at week 58. These data indicate that at week 58, filgotinib 200mg reduced and eliminated corticosteroid (CS) use compared to placebo. Severely active UC. Compared with placebo, patients who used filgotinib 200mg at week 58 and showed no CS remission had a significantly higher proportion of patients without CS in the past six months (27% filgotinib 200mg vs 6% placebo, 95% CI 21 (8 , 34 ), there was a difference as early as the first eight months (22% filgotinib 200mg vs 6% placebo, 95% CI 15 (3, 28)).2
Additional safety analysis from SELECTION, combined with induction, maintenance, and long-term extension study data, the cumulative therapeutic exposure of filgotinib 200mg was 1,207 patient-years, and placebo was 318 patient-years, showing that the results are consistent with the initial induction and maintenance trials, where filgotinib It is well tolerated in patients with moderate to severe active UC.3
Walid Abi-Saab, Chief Medical Officer of Galapagos, said: “Listening to the needs of patients with moderately and severely active UC and the healthcare professionals who treat them helps us understand how to find solutions that can address both clinical symptoms and patient reports. The importance of the treatment method. These new data from SELECTION and the long-term extended study show that compared with patients taking placebo, patients with moderate to severe active UC who took filgotinib 200 mg experienced rapid response, continuous steroid-free Remission and long-term tolerance”.
About ulcerative colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) caused by an abnormal immune system response.There are an estimated 2 million people across Europe4 Affected by IBD, including UC and Crohn’s disease (CD). It is a chronic inflammation of the gastrointestinal (GI) tract. This…
The full story on Benzinga.com
[ad_2]
Source link
